| Summary: | Axicabtagene ciloleucel (marketed as Yescarta by Gilead Sciences) is the second chimeric antigen receptor (CAR) T-cell therapy to be approved in Canada. Following a priority review, Health Canada approved axicabtagene ciloleucel on February 13, 2019, for the treatment of adult patients with relapsed or refractory (r/r) large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma, high-grade B-cell lymphoma, and DLBCL arising from follicular lymphoma. As part of CADTH's health technology assessment of axicabtagene ciloleucel, an implementation analysis and ethics review was conducted to help Canadian jurisdictions structure the provision of axicabtagene ciloleucel to adults with large B-cell lymphoma
|
|---|